cas 1896262-04-6|| where to buy (5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methanamine

Produktname:(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methanamine

IUPAC Name:1-(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methanamine

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM328353-5g	in stock	ƅǺǠȤ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1896262-04-6 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1896262-04-6; Molekulare Formel:C9H10FNO; Schmelzpunkt:-; SMILES-Code:NCC1=C(F)C=CC2=C1CCO2; Dichte:

: Katalognummer:CM328353; Molekulargewicht:167.18; Siedepunkt:; Mdl-Nr.:; Lagerung:Protect from light and store in a dry and close container at room temperature

: Benzofurans; Benzofuran is an aromatic heterocyclic organic compound with the chemical formula C8H6O. It is a colorless oily liquid at room temperature with an aromatic odor. Benzofuran can be volatilized with water vapor and can be decomposed by potassium permanganate and other oxidants. It is an intermediate for the preparation of amiodarone and indene resin. Benzofuran derivatives are important pharmaceutical intermediates.; Benzofuran | C8H6O | CID 9223 -Chemenu; Benzofuran | C8H6O | CID 9223 |Where to Buy Benzofurans; Benzofuran is the heterocyclic compound consisting of fused benzene and furan rings. This colourless liquid is a component of coal tar.Benzofuran is extracted from coal tar. It is also obtained by dehydrogenation of 2-ethylphenol.

: ORIC-944; ORIC-944 is a potent and selective allosteric inhibitor of PRC2 developed by ORIC Pharmaceuticals. Initiated dosing of ORIC-944 in combination with NUBEQA® (darolutamide) and in combination with ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer in first half of 2024. Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 in combinations with AR inhibitors for the treatment of prostate cancer.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.